X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2558) 2558
Publication (340) 340
Book Review (246) 246
Government Document (56) 56
Dissertation (24) 24
Book Chapter (22) 22
Conference Proceeding (15) 15
Magazine Article (7) 7
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1896) 1896
erbb2 (1818) 1818
humans (1624) 1624
female (1090) 1090
oncology (1084) 1084
breast cancer (875) 875
receptor, erbb-2 - metabolism (698) 698
animals (675) 675
receptor, erbb-2 - genetics (512) 512
expression (504) 504
cancer (490) 490
trastuzumab (464) 464
mice (448) 448
cell line, tumor (434) 434
cell biology (427) 427
breast neoplasms - pathology (415) 415
her2 (412) 412
biochemistry & molecular biology (401) 401
middle aged (396) 396
breast neoplasms - genetics (370) 370
breast neoplasms - metabolism (357) 357
immunohistochemistry (339) 339
adult (328) 328
aged (318) 318
prognosis (311) 311
breast-cancer (310) 310
skin and connective tissue diseases (304) 304
male (281) 281
breast neoplasms - drug therapy (276) 276
signal transduction (274) 274
phosphorylation (260) 260
research (260) 260
growth-factor receptor (252) 252
gene expression (239) 239
gene amplification (237) 237
proteins (233) 233
tumors (231) 231
egfr (228) 228
activation (225) 225
cells (223) 223
gene expression regulation, neoplastic (222) 222
amplification (221) 221
apoptosis (221) 221
receptor (221) 221
article (220) 220
genetic aspects (215) 215
growth (209) 209
overexpression (205) 205
c-erbb2 (194) 194
neoplasms (192) 192
therapy (189) 189
chemotherapy (183) 183
carcinoma (182) 182
epidermal growth factor (182) 182
pathology (181) 181
survival (180) 180
analysis (179) 179
metastasis (177) 177
aged, 80 and over (173) 173
protein (170) 170
receptor, erbb-2 - antagonists & inhibitors (165) 165
receptor, epidermal growth factor - metabolism (163) 163
monoclonal-antibody (161) 161
mutation (160) 160
genetics & heredity (158) 158
tumor cells, cultured (155) 155
kinases (154) 154
antineoplastic agents - therapeutic use (153) 153
cell proliferation (153) 153
antineoplastic agents - pharmacology (147) 147
oncogene (141) 141
antibodies, monoclonal, humanized (140) 140
genes, erbb-2 (139) 139
medicine & public health (136) 136
epidermal-growth-factor (132) 132
receptor, erbb-2 - biosynthesis (132) 132
erbb-2 protein (131) 131
care and treatment (130) 130
health aspects (130) 130
gene-expression (125) 125
lapatinib (124) 124
signal transduction - drug effects (122) 122
erbb3 (120) 120
receptor, erbb-2 - analysis (119) 119
rats (118) 118
tyrosine (117) 117
resistance (116) 116
proliferation (113) 113
blotting, western (111) 111
development and progression (111) 111
physiological aspects (111) 111
in-situ hybridization (110) 110
genes (109) 109
neu (108) 108
down-regulation (107) 107
gene (104) 104
in situ hybridization, fluorescence (104) 104
pharmacology & pharmacy (102) 102
receptor, erbb-2 - immunology (102) 102
cell proliferation - drug effects (101) 101
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2594) 2594
German (17) 17
French (14) 14
Spanish (12) 12
Korean (7) 7
Chinese (6) 6
Japanese (4) 4
Portuguese (3) 3
Turkish (2) 2
Czech (1) 1
Hungarian (1) 1
Persian (1) 1
Polish (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Frontiers in Oncology, ISSN 2234-943X, 2012, Volume 2, pp. 62 - 62
HER2-positive breast cancer accounts for 20-30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of... 
Herceptin | Targeted therapies | Breast cancer | HER2/ERBB2 | Trastuzumab | HER3 | trastuzumab | breast cancer | targeted therapies
Journal Article
07/2008
Background and Aims: Mycobacterium leprae is an obligate intracellular pathogen. Ligand-binding is an important factor in the success of chemoprevention and... 
Ligand binding | ErbB2 | Leprosy | Trastuzumab
Web Resource
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 11, pp. 9741 - 9750
A targeted therapy is recommended in case of alteration for breast and gastric carcinomas, but miscellaneous other tumor types are altered at low prevalence.... 
ERBB2/HER2 mutation | Personalized medicine | Targeted therapy | ERBB2/HER2 amplification | Trastuzumab
Journal Article
Bangladesh Journal of Medical Science, ISSN 2223-4721, 01/2019, Volume 18, Issue 1, pp. 124 - 129
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 05/2018, Volume 9, Issue 38, pp. 24914 - 24926
Pleckstrin homology-like domain family A member 2 (PHLDA2) is located within the tumor suppressor region of 11p15, and its expression is suppressed in several... 
AKT | ErbB2 | PHLDA2 | EGFR
Journal Article
Oncogene, ISSN 0950-9232, 05/2014, Volume 33, Issue 21, pp. 2779 - 2789
Journal Article
Translational Cancer Research, ISSN 2218-676X, 2016, Volume 5, Issue S1, pp. S61 - S65
Journal Article
Journal of Histochemistry & Cytochemistry, ISSN 0022-1554, 7/2019, Volume 67, Issue 7, pp. 511 - 522
The extracellular matrix proteoglycan decorin is well-known for its oncosuppressive activity. Here, decorin expression was examined in human vulva carcinoma... 
ErbB2/HER2 | oncosuppressive | Decorin cDNA | transduction | vulva carcinoma | SURVIVAL | ErbB2 | AUTOPHAGY | SUPPRESSION | CANCER | CELL BIOLOGY | GROWTH-FACTOR RECEPTOR | ENDOTHELIAL-CELLS | IN-VIVO | LIGAND | HER2 | HALLMARKS | ERLOTINIB
Journal Article
Experimental Cell Research, ISSN 0014-4827, 2010, Volume 316, Issue 15, pp. 2538 - 2553
Altered pH-regulatory ion transport is characteristic of many cancers; however, the mechanisms and consequences are poorly understood. Here, we investigate how... 
Chemotherapy | Programmed cell death | ErbB2 | HCO | cotransporter | exchanger
Journal Article
by Mao, JP and Xie, T and Gao, HL and Yan, HL and Sun, LL and Tong, PJ
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, ISSN 1940-5901, 2018, Volume 11, Issue 5, pp. 4436 - 4445
Background: The prognostic value of Her-2/ErbB-2 in patients with high-grade osteosarcoma remains controversial. Hence, we aimed to investigate the effects of... 
SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | EXTREMITIES | FACTOR RECEPTOR 2 | meta-analysis | TUMOR | prognosis | CHEMOTHERAPY | ERBB2 EXPRESSION | AMPLIFICATION | GENE | Osteosarcoma | C-ERBB2 OVEREXPRESSION | Her-2/ErbB2 | HER-2/NEU
Journal Article
襄阳职业技术学院学报, ISSN 2095-6584, 2017, Volume 16, Issue 6, pp. 82 - 84
目的探讨微小RNA-125a-5p(miR-125a-5p)过表达对乳腺癌细胞系MCF-7中erb-b2受体酪氨酸激酶2(erb-b2 receptor tyrosine kinase 2,ERBB2)基因的下调作用及对乳腺癌细胞增殖的影响。方法采用Lipofectamine... 
乳腺癌 | 增殖 | ERBB2 | miR-125a-5p
Journal Article
Journal Article
Current Pharmacogenomics and Personalized Medicine, ISSN 1875-6921, 2011, Volume 9, Issue 3, pp. 184 - 190
Acquired resistance to Herceptin is a major clinical problem in the treatment of HER2-overexpressing breast cancer. Understanding the molecular mechanisms... 
Herceptin | Bcl2 | Lapatinib | ErbB2 | Trastuzumab
Journal Article
Cell Cycle, ISSN 1538-4101, 08/2018, Volume 17, Issue 16, pp. 2027 - 2040
The heterogeneity in human breast cancer poses a challenge for effective treatment. Better understanding of tumor initiation and development will help to... 
clone evolution | epithelial-mesenchymal transition (EMT) | ErbB2/Her2 | Breast cancer | cancer stem cell | heterogeneity | ACTIVATION | TRASTUZUMAB | MECHANISM | CLONAL EVOLUTION | MESENCHYMAL TRANSITION | CELL BIOLOGY | HER2 HETEROGENEITY | MORPHOGENESIS | RESISTANCE | RADIOTHERAPY | EXPRESSION
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.